前列腺癌盆腔淋巴结超低分割与常规分割IMRT联合HDR近距离放疗:PCS-XI三期试验中期分析
PCS-XI(NCT05820633)是一项多中心三期随机非劣效试验,评估前列腺癌盆腔超低分割(UHF)对比常规分割(CF)放疗联合HDR近距离放疗和ADT的毒性与患者报告结局。中期分析纳入142例患者(CF=73,UHF=69),中位随访17.6个月,两组2-3级泌尿生殖和胃肠道毒性均低且相当,无4-5级毒性,纵向PRO轨迹平行。UHF在12个月尿失禁和18个月肠道功能方面显示有利的临床意义差异,而CF在3和9个月早期激素功能方面更优。结论认为盆腔UHF联合HDR-BT和ADT耐受性良好,支持其短期安全性和耐受性,需更长随访证明非劣效性和肿瘤学结局。
要点
- 盆腔UHF(25 Gy/5次,隔日)联合HDR-BT和ADT短期耐受性良好,2-3级GU和GI毒性低且与CF相当。
- UHF在12个月尿失禁和18个月肠道功能方面显示有利的临床意义差异。
- CF在3和9个月早期激素功能方面优于UHF。
核心结论
- 盆腔UHF联合HDR-BT和ADT与CF相比耐受性良好,支持其短期安全性和耐受性。
- 需更长随访证明非劣效性并评估肿瘤学结局。
研究设计与样本
- 多中心、三期随机非劣效试验PCS-XI(NCT05820633),预设中期分析聚焦毒性和患者报告结局。
- 纳入中危不利至极高危前列腺腺癌男性,1:1随机至CF(43 Gy/20次、44 Gy/22次或46 Gy/23次)或UHF(25 Gy/5次隔日)全盆腔放疗,联合单次15 Gy HDR-BT至前列腺及同期ADT。
- 中期分析纳入142例患者(CF=73,UHF=69),中位随访17.6个月。
主要发现
- 两组基线临床病理特征、ADT暴露和治疗体积均衡。
- 2-3级GU和GI毒性发生率低且两组相当,无4-5级毒性。
- 纵向PRO分析显示轨迹平行;UHF在12个月尿失禁和18个月肠道功能方面有有利的临床意义差异。
- CF在3和9个月早期激素功能方面更优。
关键数值与推荐
- CF方案:43 Gy/20次、44 Gy/22次或46 Gy/23次全盆腔放疗。
- UHF方案:25 Gy/5次隔日全盆腔放疗。
- HDR-BT:单次15 Gy至前列腺。
- 毒性评估采用CTCAE v5.0;PRO采用IPSS、SHIM、EPIC-26。
临床怎么用
- 盆腔UHF联合HDR-BT和ADT可作为短期耐受性良好的治疗选择,但需更长随访确认非劣效性。
- 临床决策时应考虑UHF在尿失禁和肠道功能方面的潜在优势及CF在早期激素功能方面的优势。
局限性
- 中期分析随访时间较短(中位17.6个月),不足以证明非劣效性和评估肿瘤学结局。
- 样本量有限(142例),需最终分析确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ultra-hypofractionation (UHF) has emerged as a safe and effective strategy; however, its role in prostate cancer (PCa) pelvic nodal irradiation combined with high-dose-rate brachytherapy (HDR-BT) and androgen deprivation therapy (ADT) remains insufficiently defined. PCS-XI (NCT05820633) is a multicentre, phase III randomized trial evaluating pelvic UHF versus conventionally fractionated (CF) radiotherapy. We report a prespecified interim analysis focusing on toxicity and patient-reported outcomes (PROs). METHODS: Men with unfavorable-intermediate to very-high-risk prostate adenocarcinoma were enrolled. Patients were randomized 1:1 to CF (43 Gy/20 fractions, 44 Gy/22 fractions, or 46 Gy/23 fractions) or UHF (25 Gy in 5 fractions delivered every other day) whole pelvis radiotherapy, combined with single-fraction 15 Gy HDR-BT to the prostate with concomitant ADT. Genitourinary and gastrointestinal toxicities (CTCAE v5.0) and PROs (IPSS, SHIM, EPIC-26) were collected longitudinally. RESULTS: At interim analysis, 142 patients were randomized (CF = 73; UHF = 69), with a median follow-up of 17.6 months. Baseline clinicopathologic characteristics, ADT exposure, and treatment volumes were well balanced between arms. Grade 2-3 GU and GI toxicity rates were low and comparable between arms. No grade 4-5 toxicities were observed. Longitudinal PRO analyses demonstrated parallel trajectories. Clinically meaningful differences favoring UHF were observed for urinary incontinence at 12 months and bowel function at 18 months. Conversely, the CF arm demonstrated superior early hormonal function at 3 and 9 months. CONCLUSIONS: Pelvic UHF combined with HDR-BT and ADT was well tolerated compared to CF. These findings support its short-term safety and tolerability. Longer follow-up is required to prove non-inferiority and assess oncologic outcomes.
引用
- Fabi F, Crook J, Jolicoeur M, et al. Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633). Radiother Oncol. 2026. PMID: 42134662. doi:10.1016/j.radonc.2026.111598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。